2018 Liver Cirrhosis Drug Development- Pipeline Analysis Report
Liver Cirrhosis is a catastrophic progressive GI disorder that causes irreversible scarring of the liver. Further, as it does not show symptoms in the initial stages of the disease and only presents symptoms as the disease progresses, treatment is complicated.
Over 20 companies and universities are focusing on developing treatment options for Liver Cirrhosis.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Liver Cirrhosis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Liver Cirrhosis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Liver Cirrhosis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Over 20 companies and universities are focusing on developing treatment options for Liver Cirrhosis.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Liver Cirrhosis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Liver Cirrhosis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Liver Cirrhosis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of Figures
1.2 List of Tables
2 LIVER CIRRHOSIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Liver Cirrhosis Pipeline Snapshot
2.3 Liver Cirrhosis Pipeline by Phase
2.4 Liver Cirrhosis Pipeline by Company
2.5 Liver Cirrhosis Pipeline by Mechanism of Action
3 LIVER CIRRHOSIS- COMPANY WISE PIPELINE ANALYSIS
Bristol-Myers Squibb
BIOCND Inc
Elixirgen Therapeutics LLC
Galectin Therapeutics Inc
GWOXI Stem Cell Applied Technology
International Stem Cell Corporation
Mallinckrodt Pharmaceuticals
Nimbus Therapeutics
Novartis AG
Pharmicell Co Ltd
Promethera Biosciences
Rohto Pharmaceutical Co Ltd
Synlogic
TGV-Laboratories
VESSL Therapeutics Ltd
Xfibra Inc
XTuit Pharmaceuticals
4 LIVER CIRRHOSIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN LIVER CIRRHOSIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of Figures
1.2 List of Tables
2 LIVER CIRRHOSIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Liver Cirrhosis Pipeline Snapshot
2.3 Liver Cirrhosis Pipeline by Phase
2.4 Liver Cirrhosis Pipeline by Company
2.5 Liver Cirrhosis Pipeline by Mechanism of Action
3 LIVER CIRRHOSIS- COMPANY WISE PIPELINE ANALYSIS
Bristol-Myers Squibb
BIOCND Inc
Elixirgen Therapeutics LLC
Galectin Therapeutics Inc
GWOXI Stem Cell Applied Technology
International Stem Cell Corporation
Mallinckrodt Pharmaceuticals
Nimbus Therapeutics
Novartis AG
Pharmicell Co Ltd
Promethera Biosciences
Rohto Pharmaceutical Co Ltd
Synlogic
TGV-Laboratories
VESSL Therapeutics Ltd
Xfibra Inc
XTuit Pharmaceuticals
4 LIVER CIRRHOSIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN LIVER CIRRHOSIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Liver Cirrhosis Pipeline by Phase, H1- 2018
Figure 2: Liver Cirrhosis Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Liver Cirrhosis Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
Figure 1: Liver Cirrhosis Pipeline by Phase, H1- 2018
Figure 2: Liver Cirrhosis Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Liver Cirrhosis Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Liver Cirrhosis Pipeline by Phase, H1- 2018
Table 2: Liver Cirrhosis Pipeline by Companies, H1- 2018
Table 3: Liver Cirrhosis Pipeline by Mechanism of Action, H1- 2018
Table 4: Bristol-Myers Squibb Liver Cirrhosis Pipeline, May 2018
Table 5: BIOCND Inc Liver Cirrhosis Pipeline, May 2018
Table 6: Elixirgen Therapeutics LLC Liver Cirrhosis Pipeline, May 2018
Table 7: Galectin Therapeutics Inc Liver Cirrhosis Pipeline, May 2018
Table 8: GWOXI Stem Cell Applied Technology Liver Cirrhosis Pipeline, May 2018
Table 9: International Stem Cell Corporation Liver Cirrhosis Pipeline, May 2018
Table 10: Mallinckrodt Pharmaceuticals Liver Cirrhosis Pipeline, May 2018
Table 11: Nimbus Therapeutics Liver Cirrhosis Pipeline, May 2018
Table 12: Novartis AG Liver Cirrhosis Pipeline, May 2018
Table 13: Pharmicell Co Ltd Liver Cirrhosis Pipeline, May 2018
Table 14: Promethera Biosciences Liver Cirrhosis Pipeline, May 2018
Table 15: Rohto Pharmaceutical Co Ltd Liver Cirrhosis Pipeline, May 2018
Table 16: Synlogic Liver Cirrhosis Pipeline, May 2018
Table 17: TGV-Laboratories Liver Cirrhosis Pipeline, May 2018
Table 18: VESSL Therapeutics Ltd Liver Cirrhosis Pipeline, May 2018
Table 19: Xfibra Inc Liver Cirrhosis Pipeline, May 2018
Table 20: XTuit Pharmaceuticals Liver Cirrhosis Pipeline, May 2018
Table 1: Liver Cirrhosis Pipeline by Phase, H1- 2018
Table 2: Liver Cirrhosis Pipeline by Companies, H1- 2018
Table 3: Liver Cirrhosis Pipeline by Mechanism of Action, H1- 2018
Table 4: Bristol-Myers Squibb Liver Cirrhosis Pipeline, May 2018
Table 5: BIOCND Inc Liver Cirrhosis Pipeline, May 2018
Table 6: Elixirgen Therapeutics LLC Liver Cirrhosis Pipeline, May 2018
Table 7: Galectin Therapeutics Inc Liver Cirrhosis Pipeline, May 2018
Table 8: GWOXI Stem Cell Applied Technology Liver Cirrhosis Pipeline, May 2018
Table 9: International Stem Cell Corporation Liver Cirrhosis Pipeline, May 2018
Table 10: Mallinckrodt Pharmaceuticals Liver Cirrhosis Pipeline, May 2018
Table 11: Nimbus Therapeutics Liver Cirrhosis Pipeline, May 2018
Table 12: Novartis AG Liver Cirrhosis Pipeline, May 2018
Table 13: Pharmicell Co Ltd Liver Cirrhosis Pipeline, May 2018
Table 14: Promethera Biosciences Liver Cirrhosis Pipeline, May 2018
Table 15: Rohto Pharmaceutical Co Ltd Liver Cirrhosis Pipeline, May 2018
Table 16: Synlogic Liver Cirrhosis Pipeline, May 2018
Table 17: TGV-Laboratories Liver Cirrhosis Pipeline, May 2018
Table 18: VESSL Therapeutics Ltd Liver Cirrhosis Pipeline, May 2018
Table 19: Xfibra Inc Liver Cirrhosis Pipeline, May 2018
Table 20: XTuit Pharmaceuticals Liver Cirrhosis Pipeline, May 2018
